Alpine Immune Sciences Stock Forecast, Price & News

Alpine Immune Sciences' stock was trading at $2.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALPN shares have increased by 163.9% and is now trading at $7.68.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Alpine Immune Sciences.

Alpine Immune Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Alpine Immune Sciences.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) posted its earnings results on Tuesday, August, 11th. The biotechnology company reported ($0.53) EPS for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.30. The biotechnology company earned $0.69 million during the quarter, compared to analyst estimates of $2.13 million. Alpine Immune Sciences had a negative net margin of 1,120.46% and a negative return on equity of 125.54%.
View Alpine Immune Sciences' earnings history.

6 Wall Street analysts have issued 1 year target prices for Alpine Immune Sciences' stock. Their forecasts range from $8.00 to $22.00. On average, they anticipate Alpine Immune Sciences' stock price to reach $16.80 in the next twelve months. This suggests a possible upside of 118.8% from the stock's current price.
View analysts' price targets for Alpine Immune Sciences.

Alpine Immune Sciences saw a increase in short interest in September. As of September 30th, there was short interest totaling 26,800 shares, an increase of 230.9% from the September 15th total of 8,100 shares. Based on an average daily trading volume, of 74,700 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.2% of the shares of the stock are short sold.
View Alpine Immune Sciences' Short Interest.

Some companies that are related to Alpine Immune Sciences include Frequency Therapeutics (FREQ), Syndax Pharmaceuticals (SNDX), Phibro Animal Health (PAHC), Protagonist Therapeutics (PTGX), Ocular Therapeutix (OCUL), Zafgen (ZFGN), Provention Bio (PRVB), ORIC Pharmaceuticals (ORIC), Gossamer Bio (GOSS), DiaMedica Therapeutics (DMCAF), BioSpecifics Technologies (BSTC), Radius Health (RDUS), Eagle Pharmaceuticals (EGRX), Collegium Pharmaceutical (COLL) and Cara Therapeutics (CARA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alpine Immune Sciences investors own include Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Abeona Therapeutics (ABEO), CymaBay Therapeutics (CBAY), Genocea Biosciences (GNCA), Opko Health (OPK), SCYNEXIS (SCYX), Energy Transfer (ET) and Palatin Technologies (PTN).

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

Alpine Immune Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Leonard Rickey Investment Advisors P.L.L.C. (0.07%) and Hikari Power Ltd (0.04%). Company insiders that own Alpine Immune Sciences stock include James N Topper, James Paul Rickey, Mitchell Gold and Tiger Management LLC.
View institutional ownership trends for Alpine Immune Sciences.

ALPN stock was sold by a variety of institutional investors in the last quarter, including Hikari Power Ltd.
View insider buying and selling activity for Alpine Immune Sciences.

ALPN stock was purchased by a variety of institutional investors in the last quarter, including Leonard Rickey Investment Advisors P.L.L.C.. Company insiders that have bought Alpine Immune Sciences stock in the last two years include James N Topper, James Paul Rickey, and Mitchell Gold.
View insider buying and selling activity for Alpine Immune Sciences.

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALPN stock can currently be purchased for approximately $7.68.

Alpine Immune Sciences has a market capitalization of $182.67 million and generates $1.74 million in revenue each year. The biotechnology company earns $-41,850,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. Alpine Immune Sciences employs 53 workers across the globe.

The official website for Alpine Immune Sciences is www.alpineimmunesciences.com.

Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]